| Characteristic | Overall N = 491 |
negative N = 241 |
positive and at risk N = 251 |
p-value2 |
|---|---|---|---|---|
| Age at time of sample (years) | 75 (68, 79) | 75 (69, 78) | 75 (65, 79) | 0.8 |
| Female sex | 0 (NA%) | 0 (NA%) | 0 (NA%) | |
| Race | 0.2 | |||
| 4 (8.2%) | 3 (13%) | 1 (4.0%) | ||
| black/aa | 5 (10%) | 4 (17%) | 1 (4.0%) | |
| white | 40 (82%) | 17 (71%) | 23 (92%) | |
| Ethnicity | 0.5 | |||
| 4 (8.2%) | 3 (13%) | 1 (4.0%) | ||
| hispanic/latinx | 1 (2.0%) | 0 (0%) | 1 (4.0%) | |
| not hispanic/latinx | 44 (90%) | 21 (88%) | 23 (92%) | |
| Number of immune-related adverse events (iRAEs) | 1 (1, 3) | 1 (1, 2) | 2 (1, 3) | 0.2 |
| AT1R antibody interpretation | <0.001 | |||
| at risk | 13 (27%) | 0 (0%) | 13 (52%) | |
| negative | 24 (49%) | 24 (100%) | 0 (0%) | |
| positive | 12 (24%) | 0 (0%) | 12 (48%) | |
| Death | 15 (34%) | 9 (43%) | 6 (26%) | 0.2 |
| Heart failure at baseline | 8 (18%) | 3 (14%) | 5 (21%) | 0.7 |
| Heart failure at outcome | 0.4 | |||
| 4 (8.2%) | 3 (13%) | 1 (4.0%) | ||
| 0 | 32 (65%) | 14 (58%) | 18 (72%) | |
| 1 | 12 (24%) | 7 (29%) | 5 (20%) | |
| 1 (recovered then HFrEF after ICI) | 1 (2.0%) | 0 (0%) | 1 (4.0%) | |
| Arrhythmia at baseline | >0.9 | |||
| 0 | 33 (67%) | 16 (67%) | 17 (68%) | |
| 1 | 16 (33%) | 8 (33%) | 8 (32%) | |
| Arrhythmia at outcome | 0.5 | |||
| 0 | 28 (57%) | 15 (63%) | 13 (52%) | |
| 1 | 21 (43%) | 9 (38%) | 12 (48%) | |
| New arrhythmia | 18 (37%) | 8 (33%) | 10 (40%) | 0.6 |
| ACE inhibitor or ARB use | 0.9 | |||
| 0 | 30 (61%) | 14 (58%) | 16 (64%) | |
| 0 on admission, started lisinopril 3/17/2022 | 1 (2.0%) | 1 (4.2%) | 0 (0%) | |
| 1 | 18 (37%) | 9 (38%) | 9 (36%) | |
| Spironolactone (aldactone) use | 1 (2.0%) | 0 (0%) | 1 (4.0%) | >0.9 |
| SGLT2 inhibitor use | 3 (6.1%) | 3 (13%) | 0 (0%) | 0.11 |
| Beta-blocker use | 0.8 | |||
| 0 | 26 (53%) | 12 (50%) | 14 (56%) | |
| 1 | 21 (43%) | 10 (42%) | 11 (44%) | |
| 1 (atenolol) | 1 (2.0%) | 1 (4.2%) | 0 (0%) | |
| 1 (nadolol) | 1 (2.0%) | 1 (4.2%) | 0 (0%) | |
| myocarditis_severty_adjudication | 0.4 | |||
| 1 | 4 (8.2%) | 2 (8.3%) | 2 (8.0%) | |
| 1 (asx) | 1 (2.0%) | 1 (4.2%) | 0 (0%) | |
| 1 (hypotension but likely 2/2 to other conditions) | 1 (2.0%) | 0 (0%) | 1 (4.0%) | |
| 2 | 4 (8.2%) | 3 (13%) | 1 (4.0%) | |
| 2 (cardiac MRI with signs of prior myocarditis but not active) | 1 (2.0%) | 1 (4.2%) | 0 (0%) | |
| 2 (had cMRI that does not seem conclusive for myocarditis, had CP) | 1 (2.0%) | 0 (0%) | 1 (4.0%) | |
| 2 (Had CP but likely due to pericardial effusion) | 1 (2.0%) | 0 (0%) | 1 (4.0%) | |
| 2 (mildly reduced EF but no clear sx) | 1 (2.0%) | 0 (0%) | 1 (4.0%) | |
| 2 (new DOE) | 1 (2.0%) | 0 (0%) | 1 (4.0%) | |
| 2 (normal echo, ? cardiogenic syncope) | 1 (2.0%) | 0 (0%) | 1 (4.0%) | |
| 2 (unstable but for other reasons) | 1 (2.0%) | 0 (0%) | 1 (4.0%) | |
| 2/3 (Formal MRI didn't read myocarditis, but per notes Dr. Kwan thought was consistent) | 1 (2.0%) | 1 (4.2%) | 0 (0%) | |
| 3 | 17 (35%) | 8 (33%) | 9 (36%) | |
| 3 (based on MRI) | 1 (2.0%) | 0 (0%) | 1 (4.0%) | |
| 3 (cMRI 11/2022 with myocarditis) | 1 (2.0%) | 0 (0%) | 1 (4.0%) | |
| 3 (cMRI suggestive and TTE with known apical akinesis iso scar) | 1 (2.0%) | 1 (4.2%) | 0 (0%) | |
| 3 (EF 25 - 30% w/ sx but no instability) | 1 (2.0%) | 1 (4.2%) | 0 (0%) | |
| 3 (EF drop w/ CP but no instability) | 1 (2.0%) | 0 (0%) | 1 (4.0%) | |
| 3 (In MICU but for AHRF 2/2 lung dz) | 1 (2.0%) | 0 (0%) | 1 (4.0%) | |
| 3 (MRI read equivocal but seems real enough) | 1 (2.0%) | 1 (4.2%) | 0 (0%) | |
| 4 | 6 (12%) | 5 (21%) | 1 (4.0%) | |
| 4 (aggressively worsening trops despite immunosupp, hypotension likely iso sepsis but seems like grade 4) | 1 (2.0%) | 0 (0%) | 1 (4.0%) | |
| Prolonged immunosuppression | 25 (60%) | 10 (50%) | 15 (68%) | 0.2 |
| Number of non-HLA positive beads | 4 (1, 12) | 1 (1, 5) | 10 (4, 16) | 0.024 |
| Metastatic cancer | 10 (77%) | 5 (63%) | 5 (100%) | 0.2 |
| Hypertension | 42 (93%) | 21 (100%) | 21 (88%) | 0.2 |
| Hyperlipidemia | 37 (82%) | 16 (76%) | 21 (88%) | 0.4 |
| Coronary artery disease | 28 (62%) | 13 (62%) | 15 (63%) | >0.9 |
| Diabetes mellitus | 10 (22%) | 7 (33%) | 3 (13%) | 0.2 |
| Heart failure | 14 (31%) | 6 (29%) | 8 (33%) | 0.7 |
| Valvular disease | 2 (4.4%) | 2 (9.5%) | 0 (0%) | 0.2 |
| Ipilimumab (IPI) | 11 (24%) | 3 (14%) | 8 (33%) | 0.14 |
| Nivolumab (NIVO) | 16 (36%) | 6 (29%) | 10 (42%) | 0.4 |
| Pembrolizumab (PEMBRO) | 24 (53%) | 12 (57%) | 12 (50%) | 0.6 |
| Durvalumab (DURVA) | 5 (11%) | 2 (9.5%) | 3 (13%) | >0.9 |
| Atezolizumab (ATEZO) | 5 (11%) | 2 (9.5%) | 3 (13%) | >0.9 |
| Days from initial ICI exposure to presentation | 75 (33, 333) | 67 (35, 239) | 75 (31, 594) | 0.8 |
| Pulse-dose steroids given | 42 (93%) | 20 (95%) | 22 (92%) | >0.9 |
| Prolonged steroid course after pulse | 22 (49%) | 11 (52%) | 11 (46%) | 0.7 |
| Mycophenolate mofetil (MMF) | 25 (56%) | 13 (62%) | 12 (50%) | 0.4 |
| Abatacept | 17 (38%) | 9 (43%) | 8 (33%) | 0.5 |
| IVIG | 10 (22%) | 4 (19%) | 6 (25%) | 0.7 |
| Infliximab | 2 (4.4%) | 2 (9.5%) | 0 (0%) | 0.2 |
| Tofacitinib | 11 (24%) | 6 (29%) | 5 (21%) | 0.5 |
| Any immunosuppression escalation | 25 (56%) | 10 (48%) | 15 (63%) | 0.3 |
| Number of immunosuppression escalations | 1.00 (0.00, 1.00) | 0.00 (0.00, 1.00) | 1.00 (0.00, 1.00) | 0.4 |
| LVEF (%) — clinical | 58 (48, 63) | 54 (41, 59) | 58 (48, 64) | 0.2 |
| RVEF (%) — clinical | 49 (45, 56) | 46 (39, 50) | 52 (49, 63) | 0.015 |
| Cardiomyopathy etiology | 0.7 | |||
| 10 (24%) | 5 (25%) | 5 (24%) | ||
| 0 | 1 (2.4%) | 1 (5.0%) | 0 (0%) | |
| both | 2 (4.9%) | 0 (0%) | 2 (9.5%) | |
| ischemic | 1 (2.4%) | 1 (5.0%) | 0 (0%) | |
| ischemic_nonischemic_both_sheet_4 | 3 (7.3%) | 1 (5.0%) | 2 (9.5%) | |
| nonischemic | 24 (59%) | 12 (60%) | 12 (57%) | |
| Other irAEs | >0.9 | |||
| 47 (96%) | 23 (96%) | 24 (96%) | ||
| myositis, MG myocarditis | 1 (2.0%) | 0 (0%) | 1 (4.0%) | |
| pneumonitis | 1 (2.0%) | 1 (4.2%) | 0 (0%) | |
| Native T1, CMR (ms) | 992 (961, 1,016) | 1,002 (982, 1,016) | 971 (946, 1,042) | 0.5 |
| ECV, CMR (%) — categories | 29.0 (24.5, 35.5) | 31.0 (26.0, 36.0) | 28.5 (23.0, 34.0) | 0.7 |
| T2 (0=normal, 1=elevated) | 19 (56%) | 9 (50%) | 10 (63%) | 0.5 |
| matt_for_sure_ischemic_lge | 1 (25%) | 1 (33%) | 0 (0%) | >0.9 |
| LGE burden, CMR (% LV mass) | 7 (3, 12) | 7 (0, 10) | 8 (4, 12) | 0.5 |
| CM outcome (1 = event) | ||||
| 1 | 14 (100%) | 6 (100%) | 8 (100%) | |
| LVEF, CMR (%) | 59 (51, 64) | 60 (53, 63) | 58 (50, 68) | 0.7 |
| RVEF, CMR (%) | 52 (48, 56) | 52 (49, 54) | 51 (45, 58) | >0.9 |
| LV wall thickness (AP), mm | 10.00 (8.00, 11.00) | 10.00 (8.00, 11.00) | 11.00 (8.00, 11.00) | 0.6 |
| LV wall thickness (PL), mm | 8.00 (7.00, 9.50) | 8.00 (6.00, 9.00) | 8.00 (7.00, 10.00) | 0.4 |
| Global radial strain, CMR (%) | 26 (21, 36) | 29 (21, 35) | 23 (21, 36) | 0.8 |
| Global circumferential strain, CMR (%) | -17.7 (-19.9, -14.2) | -17.9 (-20.1, -13.8) | -15.3 (-19.8, -14.2) | >0.9 |
| Global longitudinal strain (GLS), CMR (%) | -13.6 (-15.5, -10.8) | -14.6 (-17.3, -12.0) | -13.0 (-15.3, -10.0) | 0.2 |
| Abnormal GLS | 34 (85%) | 15 (83%) | 19 (86%) | >0.9 |
| MAPSE — anterior (mm) | 10.0 (7.2, 12.4) | 10.4 (5.9, 14.4) | 9.7 (7.3, 11.7) | 0.5 |
| MAPSE — inferior (mm) | 11.7 (9.7, 14.5) | 13.1 (10.2, 14.6) | 10.6 (8.9, 13.3) | 0.2 |
| MAPSE — mean (mm) | 10.2 (8.5, 12.5) | 11.6 (7.8, 14.0) | 10.0 (8.6, 12.0) | 0.4 |
| remove_variavle | NA (NA, NA) | NA (NA, NA) | NA (NA, NA) | |
| 1 Median (Q1, Q3); n (%) | ||||
| 2 Wilcoxon rank sum test; NA; Fisher’s exact test; Pearson’s Chi-squared test | ||||
initialization_att1r_project
Quarto
Positive vs non-positive
Negative vs non-negative
Removed all “at risk”
| Characteristic | Overall N = 361 |
negative N = 241 |
positive N = 121 |
p-value2 |
|---|---|---|---|---|
| Age at time of sample (years) | 76 (69, 79) | 75 (69, 78) | 77 (73, 81) | 0.4 |
| Female sex | 0 (NA%) | 0 (NA%) | 0 (NA%) | |
| Race | 0.5 | |||
| 4 (11%) | 3 (13%) | 1 (8.3%) | ||
| black/aa | 4 (11%) | 4 (17%) | 0 (0%) | |
| white | 28 (78%) | 17 (71%) | 11 (92%) | |
| Ethnicity | 0.5 | |||
| 4 (11%) | 3 (13%) | 1 (8.3%) | ||
| hispanic/latinx | 1 (2.8%) | 0 (0%) | 1 (8.3%) | |
| not hispanic/latinx | 31 (86%) | 21 (88%) | 10 (83%) | |
| Number of immune-related adverse events (iRAEs) | 1 (1, 2) | 1 (1, 2) | 1 (1, 3) | 0.9 |
| AT1R antibody interpretation | <0.001 | |||
| negative | 24 (67%) | 24 (100%) | 0 (0%) | |
| positive | 12 (33%) | 0 (0%) | 12 (100%) | |
| Death | 11 (34%) | 9 (43%) | 2 (18%) | 0.2 |
| Heart failure at baseline | 6 (19%) | 3 (14%) | 3 (27%) | 0.4 |
| Heart failure at outcome | 0.7 | |||
| 4 (11%) | 3 (13%) | 1 (8.3%) | ||
| 0 | 23 (64%) | 14 (58%) | 9 (75%) | |
| 1 | 9 (25%) | 7 (29%) | 2 (17%) | |
| Arrhythmia at baseline | >0.9 | |||
| 0 | 24 (67%) | 16 (67%) | 8 (67%) | |
| 1 | 12 (33%) | 8 (33%) | 4 (33%) | |
| Arrhythmia at outcome | >0.9 | |||
| 0 | 22 (61%) | 15 (63%) | 7 (58%) | |
| 1 | 14 (39%) | 9 (38%) | 5 (42%) | |
| New arrhythmia | 13 (36%) | 8 (33%) | 5 (42%) | 0.7 |
| ACE inhibitor or ARB use | 0.3 | |||
| 0 | 24 (67%) | 14 (58%) | 10 (83%) | |
| 0 on admission, started lisinopril 3/17/2022 | 1 (2.8%) | 1 (4.2%) | 0 (0%) | |
| 1 | 11 (31%) | 9 (38%) | 2 (17%) | |
| Spironolactone (aldactone) use | ||||
| 0 | 36 (100%) | 24 (100%) | 12 (100%) | |
| SGLT2 inhibitor use | 3 (8.3%) | 3 (13%) | 0 (0%) | 0.5 |
| Beta-blocker use | >0.9 | |||
| 0 | 19 (53%) | 12 (50%) | 7 (58%) | |
| 1 | 15 (42%) | 10 (42%) | 5 (42%) | |
| 1 (atenolol) | 1 (2.8%) | 1 (4.2%) | 0 (0%) | |
| 1 (nadolol) | 1 (2.8%) | 1 (4.2%) | 0 (0%) | |
| myocarditis_severty_adjudication | 0.8 | |||
| 1 | 4 (11%) | 2 (8.3%) | 2 (17%) | |
| 1 (asx) | 1 (2.8%) | 1 (4.2%) | 0 (0%) | |
| 1 (hypotension but likely 2/2 to other conditions) | 1 (2.8%) | 0 (0%) | 1 (8.3%) | |
| 2 | 4 (11%) | 3 (13%) | 1 (8.3%) | |
| 2 (cardiac MRI with signs of prior myocarditis but not active) | 1 (2.8%) | 1 (4.2%) | 0 (0%) | |
| 2 (new DOE) | 1 (2.8%) | 0 (0%) | 1 (8.3%) | |
| 2 (normal echo, ? cardiogenic syncope) | 1 (2.8%) | 0 (0%) | 1 (8.3%) | |
| 2/3 (Formal MRI didn't read myocarditis, but per notes Dr. Kwan thought was consistent) | 1 (2.8%) | 1 (4.2%) | 0 (0%) | |
| 3 | 13 (36%) | 8 (33%) | 5 (42%) | |
| 3 (cMRI suggestive and TTE with known apical akinesis iso scar) | 1 (2.8%) | 1 (4.2%) | 0 (0%) | |
| 3 (EF 25 - 30% w/ sx but no instability) | 1 (2.8%) | 1 (4.2%) | 0 (0%) | |
| 3 (MRI read equivocal but seems real enough) | 1 (2.8%) | 1 (4.2%) | 0 (0%) | |
| 4 | 6 (17%) | 5 (21%) | 1 (8.3%) | |
| Prolonged immunosuppression | 18 (62%) | 10 (50%) | 8 (89%) | 0.10 |
| Number of non-HLA positive beads | 5 (1, 17) | 1 (1, 5) | 23 (15, 29) | 0.010 |
| Metastatic cancer | 7 (70%) | 5 (63%) | 2 (100%) | >0.9 |
| Hypertension | 30 (94%) | 21 (100%) | 9 (82%) | 0.11 |
| Hyperlipidemia | 26 (81%) | 16 (76%) | 10 (91%) | 0.6 |
| Coronary artery disease | 23 (72%) | 13 (62%) | 10 (91%) | 0.11 |
| Diabetes mellitus | 8 (25%) | 7 (33%) | 1 (9.1%) | 0.2 |
| Heart failure | 10 (31%) | 6 (29%) | 4 (36%) | 0.7 |
| Valvular disease | 2 (6.3%) | 2 (9.5%) | 0 (0%) | 0.5 |
| Ipilimumab (IPI) | 7 (22%) | 3 (14%) | 4 (36%) | 0.2 |
| Nivolumab (NIVO) | 10 (31%) | 6 (29%) | 4 (36%) | 0.7 |
| Pembrolizumab (PEMBRO) | 19 (59%) | 12 (57%) | 7 (64%) | >0.9 |
| Durvalumab (DURVA) | 4 (13%) | 2 (9.5%) | 2 (18%) | 0.6 |
| Atezolizumab (ATEZO) | 3 (9.4%) | 2 (9.5%) | 1 (9.1%) | >0.9 |
| Days from initial ICI exposure to presentation | 82 (35, 455) | 67 (35, 239) | 145 (50, 1,009) | 0.2 |
| Pulse-dose steroids given | 29 (91%) | 20 (95%) | 9 (82%) | 0.3 |
| Prolonged steroid course after pulse | 17 (53%) | 11 (52%) | 6 (55%) | >0.9 |
| Mycophenolate mofetil (MMF) | 19 (59%) | 13 (62%) | 6 (55%) | 0.7 |
| Abatacept | 13 (41%) | 9 (43%) | 4 (36%) | >0.9 |
| IVIG | 8 (25%) | 4 (19%) | 4 (36%) | 0.4 |
| Infliximab | 2 (6.3%) | 2 (9.5%) | 0 (0%) | 0.5 |
| Tofacitinib | 7 (22%) | 6 (29%) | 1 (9.1%) | 0.4 |
| Any immunosuppression escalation | 18 (56%) | 10 (48%) | 8 (73%) | 0.3 |
| Number of immunosuppression escalations | 1.00 (0.00, 1.00) | 0.00 (0.00, 1.00) | 1.00 (0.00, 2.00) | 0.2 |
| LVEF (%) — clinical | 58 (54, 62) | 54 (41, 59) | 64 (58, 64) | 0.023 |
| RVEF (%) — clinical | 49 (44, 52) | 46 (39, 50) | 58 (50, 66) | 0.040 |
| Cardiomyopathy etiology | 0.3 | |||
| 9 (30%) | 5 (25%) | 4 (40%) | ||
| 0 | 1 (3.3%) | 1 (5.0%) | 0 (0%) | |
| both | 1 (3.3%) | 0 (0%) | 1 (10%) | |
| ischemic | 1 (3.3%) | 1 (5.0%) | 0 (0%) | |
| ischemic_nonischemic_both_sheet_4 | 3 (10%) | 1 (5.0%) | 2 (20%) | |
| nonischemic | 15 (50%) | 12 (60%) | 3 (30%) | |
| Other irAEs | 0.6 | |||
| 34 (94%) | 23 (96%) | 11 (92%) | ||
| myositis, MG myocarditis | 1 (2.8%) | 0 (0%) | 1 (8.3%) | |
| pneumonitis | 1 (2.8%) | 1 (4.2%) | 0 (0%) | |
| Native T1, CMR (ms) | 991 (957, 1,015) | 1,002 (982, 1,016) | 953 (938, 977) | 0.2 |
| ECV, CMR (%) — categories | 27.0 (26.0, 36.0) | 31.0 (26.0, 36.0) | 26.0 (23.0, 40.0) | >0.9 |
| T2 (0=normal, 1=elevated) | 14 (52%) | 9 (50%) | 5 (56%) | >0.9 |
| matt_for_sure_ischemic_lge | 1 (25%) | 1 (33%) | 0 (0%) | >0.9 |
| LGE burden, CMR (% LV mass) | 8 (0, 13) | 7 (0, 10) | 11 (4, 15) | 0.3 |
| CM outcome (1 = event) | ||||
| 1 | 8 (100%) | 6 (100%) | 2 (100%) | |
| LVEF, CMR (%) | 60 (54, 64) | 60 (53, 63) | 62 (58, 68) | 0.2 |
| RVEF, CMR (%) | 52 (49, 55) | 52 (49, 54) | 53 (48, 58) | 0.5 |
| LV wall thickness (AP), mm | 10.00 (8.00, 11.00) | 10.00 (8.00, 11.00) | 9.00 (6.50, 11.00) | 0.7 |
| LV wall thickness (PL), mm | 8.00 (7.00, 9.00) | 8.00 (6.00, 9.00) | 8.50 (7.00, 10.50) | 0.3 |
| Global radial strain, CMR (%) | 29 (22, 36) | 29 (21, 35) | 34 (23, 36) | 0.3 |
| Global circumferential strain, CMR (%) | -18.1 (-20.1, -14.7) | -17.9 (-20.1, -13.8) | -18.6 (-20.0, -15.1) | 0.5 |
| Global longitudinal strain (GLS), CMR (%) | -14.7 (-16.7, -11.9) | -14.6 (-17.3, -12.0) | -14.9 (-15.5, -10.8) | >0.9 |
| Abnormal GLS | 25 (83%) | 15 (83%) | 10 (83%) | >0.9 |
| MAPSE — anterior (mm) | 10.2 (6.8, 12.9) | 10.4 (5.9, 14.4) | 10.1 (7.3, 12.2) | 0.8 |
| MAPSE — inferior (mm) | 12.4 (9.8, 14.5) | 13.1 (10.2, 14.6) | 10.5 (9.7, 12.9) | 0.3 |
| MAPSE — mean (mm) | 10.9 (8.6, 12.8) | 11.6 (7.8, 14.0) | 10.9 (8.9, 12.0) | 0.8 |
| remove_variavle | NA (NA, NA) | NA (NA, NA) | NA (NA, NA) | |
| 1 Median (Q1, Q3); n (%) | ||||
| 2 Wilcoxon rank sum test; NA; Fisher’s exact test; Pearson’s Chi-squared test; Wilcoxon rank sum exact test | ||||
Clean table for abstract
| Characteristic | Overall N = 361 |
negative N = 241 |
positive N = 121 |
p-value2 |
|---|---|---|---|---|
| Age at time of sample (years) | 76 (69, 79) | 75 (69, 78) | 77 (73, 81) | 0.4 |
| Female sex | 0 (NA%) | 0 (NA%) | 0 (NA%) | |
| Race | 0.5 | |||
| 4 (11%) | 3 (13%) | 1 (8.3%) | ||
| black/aa | 4 (11%) | 4 (17%) | 0 (0%) | |
| white | 28 (78%) | 17 (71%) | 11 (92%) | |
| Ethnicity | 0.5 | |||
| 4 (11%) | 3 (13%) | 1 (8.3%) | ||
| hispanic/latinx | 1 (2.8%) | 0 (0%) | 1 (8.3%) | |
| not hispanic/latinx | 31 (86%) | 21 (88%) | 10 (83%) | |
| Death | 11 (34%) | 9 (43%) | 2 (18%) | 0.2 |
| Prolonged immunosuppression | 18 (62%) | 10 (50%) | 8 (89%) | 0.10 |
| Number of non-HLA positive beads | 5 (1, 17) | 1 (1, 5) | 23 (15, 29) | 0.010 |
| Hypertension | 30 (94%) | 21 (100%) | 9 (82%) | 0.11 |
| Hyperlipidemia | 26 (81%) | 16 (76%) | 10 (91%) | 0.6 |
| Coronary artery disease | 23 (72%) | 13 (62%) | 10 (91%) | 0.11 |
| Diabetes mellitus | 8 (25%) | 7 (33%) | 1 (9.1%) | 0.2 |
| Heart failure | 10 (31%) | 6 (29%) | 4 (36%) | 0.7 |
| LGE burden, CMR (% LV mass) | 8 (0, 13) | 7 (0, 10) | 11 (4, 15) | 0.3 |
| LVEF, CMR (%) | 60 (54, 64) | 60 (53, 63) | 62 (58, 68) | 0.2 |
| RVEF, CMR (%) | 52 (49, 55) | 52 (49, 54) | 53 (48, 58) | 0.5 |
| LV wall thickness (AP), mm | 10.00 (8.00, 11.00) | 10.00 (8.00, 11.00) | 9.00 (6.50, 11.00) | 0.7 |
| LV wall thickness (PL), mm | 8.00 (7.00, 9.00) | 8.00 (6.00, 9.00) | 8.50 (7.00, 10.50) | 0.3 |
| Global radial strain, CMR (%) | 29 (22, 36) | 29 (21, 35) | 34 (23, 36) | 0.3 |
| Global circumferential strain, CMR (%) | -18.1 (-20.1, -14.7) | -17.9 (-20.1, -13.8) | -18.6 (-20.0, -15.1) | 0.5 |
| Global longitudinal strain (GLS), CMR (%) | -14.7 (-16.7, -11.9) | -14.6 (-17.3, -12.0) | -14.9 (-15.5, -10.8) | >0.9 |
| Abnormal GLS | 25 (83%) | 15 (83%) | 10 (83%) | >0.9 |
| 1 Median (Q1, Q3); n (%) | ||||
| 2 Wilcoxon rank sum test; NA; Fisher’s exact test | ||||